SCHEMBL6785353

SCHEMBL6785353

Cn1ncc(Nc2ccc(F)cc2)c1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 5/20 0.58
PDE10A Q9Y233 2/20 0.53
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
BRD4 O60885 3/20 0.43
KAT2B Q92831 2/20 0.43
BRD9 Q9H8M2 1/20 0.43
GAA P10253 1/20 0.43
HTR2C P28335 4/20 0.42
DHODH Q02127 1/20 0.40
PTK2 Q05397 1/20 0.40
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786160 0.87 BPTF (0.44) BPTFPDE10AKMT2ASMN1; SMN2BRD4
SCHEMBL4354244 0.86 BPTF (0.56) BPTFPDE10AKMT2ASMN1; SMN2GAA
SCHEMBL6789292 0.85 SMN1; SMN2 (0.48) BPTFPDE10AKMT2ASMN1; SMN2BRD4
SCHEMBL6784797 0.83 PDE10A (0.56) BPTFPDE10ASMN1; SMN2BRD4KAT2B
SCHEMBL6786035 0.81 FLT1 (0.56) BPTFPDE10ABRD4KAT2BBRD9
SCHEMBL6784809 0.78 CXCL8 (0.46) BPTFSMN1; SMN2BRD4KAT2BBRD9
SCHEMBL1777658 0.74 LPAR1 (0.42) KMT2ASMN1; SMN2GAAKDM4EMEN1
SCHEMBL26910162 0.73 BPTF (1.00) BPTFBRD4KAT2BBRD9
SCHEMBL6787123 0.73 BPTF (0.50) BPTFPDE10ASMN1; SMN2BRD4KAT2B
SCHEMBL6786512 0.71 BPTF (0.48) BPTFSMN1; SMN2BRD4KAT2BBRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686373-B2 ANALGESICS; ANTIINFLAMMATORY AGENT WARNER-LAMBERT COMPANY LLC 2004-02-03 US disclosed
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors KAWAMURA KIYOSHI (JP) 2003-07-10 US disclosed
EP-1310498-A2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PFIZER INC. (US) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PRKCB, PRKCA, PRKCG BPTF 4059/4885PDE10A 2059/4885KMT2A 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.